Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Indian Science
  4. Volume 2, Issue 1
  5. Article
Volume 2, Issue 1
  • ISSN: 2210-299X
  • E-ISSN: 2210-3007
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

A chronic skin condition called psoriasis can manifest as plaque, flexural, guttate, pustular, and erythrodermic lesions, among other clinical symptoms. Sixty million people are believed to be affected by psoriasis worldwide. In India, the frequency ranges from 0.44 to 2.8%, with males affected two times more frequently than females in their third or fourth decade of life. An immune-mediated inflammation condition with a sizable genetic component is psoriasis. Due to its connection to psoriatic arthritis and the increased prevalence of cardiometabolic, hepatic, and psychiatric problems, a thorough and interdisciplinary strategy for treatment is required. Corticosteroids and analogs of vitamin D are examples of topical treatments for psoriasis. Phototherapy includes NB-UVB, psoralen, and ultraviolet radiation (PUVA). Standard systemic treatments include methotrexate, acitretin, and ciclosporin. This disease is useful for physicians and scientists since it might be used as a model for research into the underlying causes of chronic inflammation. It is also crucial for clinical trial scientists as a first-choice disease indication for preliminary research of new pathogenesis-based treatment approaches. This review covers both the therapeutic choices that have resulted from the analysis of the aggressive psoriatic pathways and the processes involved in the onset and progression of the disease. We start by writing regarding the important cell kinds and inflammatory mechanisms that initiate and maintain psoriatic inflammation. Next, we discuss how skin flora interacts with heredity, related epigenetic processes, and the pathogenesis of psoriasis. Finally, we provide a thorough analysis of recently targeted medications as well as well-known, extensively used treatments.

© 2024 The Author(s). Published by Bentham Science Publisher.
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Loading

Article metrics loading...

/content/journals/cis/10.2174/012210299X256032231127060853
2024-01-01
2024-11-26

  • From This Site

    /content/journals/cis/10.2174/012210299X256032231127060853
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cis/2/1/CIS-2-E2210299X256032.html?itemId=/content/journals/cis/10.2174/012210299X256032231127060853&mimeType=html&fmt=ahah

References

  1. Expert Committee on Biological Standardization, World Health Organization. WHO Expert Committee on Biological Standardization: Sixty-sixth Report.World Health Organization2016
  2. GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.Lancet2017390101001260134410.1016/S0140‑6736(17)32130‑X28919118
     [Google Scholar]
  3. Di MeglioP. VillanovaF. NestleF.O. Psoriasis.Cold Spring Harb. Perspect. Med.201448a01535410.1101/cshperspect.a01535425085957
     [Google Scholar]
  4. ParisiR. SymmonsD.P.M. GriffithsC.E.M. AshcroftD.M. Global epidemiology of psoriasis: A systematic review of incidence and prevalence.J. Invest. Dermatol.2013133237738510.1038/jid.2012.33923014338
     [Google Scholar]
  5. VealC.D. CloughR.L. BarberR.C. MasonS. TillmanD. FerryB. JonesA.B. AmeenM. BalendranN. PowisS.H. BurdenA.D. BarkerJ.N.W.N. TrembathR.C. Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate loci.J. Med. Genet.200138171310.1136/jmg.38.1.711134234
     [Google Scholar]
  6. NairR.P. StuartP. HenselerT. JenischS. ChiaN.V.C. WestphalE. SchorkN.J. KimJ. LimH.W. ChristophersE. VoorheesJ.J. ElderJ.T. Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C.Am. J. Hum. Genet.20006661833184410.1086/30293210801386
     [Google Scholar]
  7. GriffithsC.E.M. ChristophersE. BarkerJ.N.W.N. ChalmersR.J.G. ChimentiS. KruegerG.G. LeonardiC. MenterA. OrtonneJ.P. FryL. A classification of psoriasis vulgaris according to phenotype.Br. J. Dermatol.2007156225826210.1111/j.1365‑2133.2006.07675.x17223864
     [Google Scholar]
  8. HenselerT. ChristophersE. Psoriasis of early and late onset: Characterization of two types of psoriasis vulgaris.J. Am. Acad. Dermatol.198513345045610.1016/S0190‑9622(85)70188‑04056119
     [Google Scholar]
  9. HawkinsR.D. ByrneJ.H. Associative learning in invertebrates.Cold Spring Harb. Perspect. Biol.201575a02170910.1101/cshperspect.a02170925877219
     [Google Scholar]
  10. RendonA. SchäkelK. Psoriasis pathogenesis and treatment.Int. J. Mol. Sci.2019206147510.3390/ijms2006147530909615
     [Google Scholar]
  11. O’DohertyC.J. MacIntyreC. Palmoplantar pustulosis and smoking.BMJ1985291649986186410.1136/bmj.291.6499.8613931743
     [Google Scholar]
  12. Setta-KaffetziN. NavariniA.A. PatelV.M. PullabhatlaV. PinkA.E. ChoonS.E. AllenM.A. BurdenA.D. GriffithsC.E.M. SeygerM.M.B. KirbyB. TrembathR.C. SimpsonM.A. SmithC.H. CaponF. BarkerJ.N. Rare pathogenic variants in IL36RN underlie a spectrum of psoriasis-associated pustular phenotypes.J. Invest. Dermatol.201313351366136910.1038/jid.2012.49023303454
     [Google Scholar]
  13. GladmanD.D. AntoniC. MeaseP. CleggD.O. NashP. Psoriatic arthritis: Epidemiology, clinical features, course, and outcome.Ann. Rheum. Dis.200564Suppl 2ii14ii1710.1136/ard.2004.03248215708927
     [Google Scholar]
  14. EllinghausE. StuartP.E. EllinghausD. NairR.P. DebrusS. RaelsonJ.V. BelouchiM. TejasviT. LiY. TsoiL.C. OnkenA.T. EskoT. MetspaluA. RahmanP. GladmanD.D. BowcockA.M. HelmsC. KruegerG.G. KoksS. KingoK. GiegerC. Erich WichmannH. MrowietzU. WeidingerS. SchreiberS. AbecasisG.R. ElderJ.T. WeichenthalM. FrankeA. Genome-wide meta-analysis of psoriatic arthritis identifies susceptibility locus at REL.J. Invest. Dermatol.201213241133114010.1038/jid.2011.41522170493
     [Google Scholar]
  15. GarbaravicieneJ. DiehlS. VarwigD. BylaiteM. AckermannH. LudwigR.J. BoehnckeW.H. Platelet P-selectin reflects a state of cutaneous inflammation: Possible application to monitor treatment efficacy in psoriasis.Exp. Dermatol.201019873674110.1111/j.1600‑0625.2010.01095.x20482619
     [Google Scholar]
  16. LeeE. TrepicchioW.L. OestreicherJ.L. PittmanD. WangF. ChamianF. DhodapkarM. KruegerJ.G. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris.J. Exp. Med.2004199112513010.1084/jem.2003045114707118
     [Google Scholar]
  17. TejasviT. StuartP.E. ChandranV. VoorheesJ.J. GladmanD.D. RahmanP. ElderJ.T. NairR.P. TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis.J. Invest. Dermatol.2012132359360010.1038/jid.2011.37622113471
     [Google Scholar]
  18. Suárez-FariñasM. Fuentes-DuculanJ. LowesM.A. KruegerJ.G. Resolved psoriasis lesions retain expression of a subset of disease-related genes.J. Invest. Dermatol.2011131239140010.1038/jid.2010.28020861854
     [Google Scholar]
  19. Braun-FalcoO. BurgG. Das entz�ndliche Infiltrat bei Psoriasis vulgaris.Arch. Dermatol. Res.1970236329731410.1007/BF00508329
     [Google Scholar]
  20. NestleF.O. NickoloffB.J. Role of dendritic cells in benign and malignant lymphocytic infiltrates of the skin.Dermatol. Clin.199412227128210.1016/S0733‑8635(18)30174‑87913887
     [Google Scholar]
  21. NickoloffB.J. Skin innate immune system in psoriasis: Friend or foe?J. Clin. Invest.199910491161116410.1172/JCI863310545511
     [Google Scholar]
  22. NestleF.O. ConradC. Tun-KyiA. HomeyB. GombertM. BoymanO. BurgG. LiuY.J. GillietM. Plasmacytoid predendritic cells initiate psoriasis through interferon-α production.J. Exp. Med.2005202113514310.1084/jem.2005050015998792
     [Google Scholar]
  23. BüchauA.S. GalloR.L. Innate immunity and antimicrobial defense systems in psoriasis.Clin. Dermatol.200725661662410.1016/j.clindermatol.2007.08.01618021900
     [Google Scholar]
  24. NestleF.O. TurkaL.A. NickoloffB.J. Characterization of dermal dendritic cells in psoriasis. Autostimulation of T lymphocytes and induction of Th1 type cytokines.J. Clin. Invest.199494120220910.1172/JCI1173088040262
     [Google Scholar]
  25. ChamianF. LowesM.A. LinS.L. LeeE. KikuchiT. GilleaudeauP. Sullivan-WhalenM. CardinaleI. KhatcherianA. NovitskayaI. WittkowskiK.M. KruegerJ.G. Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris.Proc. Natl. Acad. Sci.200510262075208010.1073/pnas.040956910215671179
     [Google Scholar]
  26. StratisA. PasparakisM. RupecR.A. MarkurD. HartmannK. Scharffetter-KochanekK. PetersT. van RooijenN. KriegT. HaaseI. Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation.J. Clin. Invest.200611682094210410.1172/JCI2717916886058
     [Google Scholar]
  27. TeunissenM.B.M. BosJ.D. KoomenC.W. de Waal MalefytR. WierengaE.A. Interleukin-17 and interferon-γ synergize in the enhancement of proinflammatory cytokine production by human keratinocytes.J. Invest. Dermatol.1998111464564910.1046/j.1523‑1747.1998.00347.x9764847
     [Google Scholar]
  28. NickoloffB.J. The cytokine network in psoriasis.Arch. Dermatol.1991127687188410.1001/archderm.1991.016800501150152036036
     [Google Scholar]
  29. SugiyamaH. GyulaiR. ToichiE. GaracziE. ShimadaS. StevensS.R. McCormickT.S. CooperK.D. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: Mechanism underlying unrestrained pathogenic effector T cell proliferation.J. Immunol.2005174116417310.4049/jimmunol.174.1.16415611238
     [Google Scholar]
  30. WangH. PetersT. SindrilaruA. KessD. OreshkovaT. YuX.Z. SeierA.M. SchreiberH. WlaschekM. BlakytnyR. RöhrbeinJ. SchulzG. WeissJ.M. Scharffetter-KochanekK. TGF-β–dependent suppressive function of Tregs requires wild-type levels of CD18 in a mouse model of psoriasis.J. Clin. Invest.200811872629263910.1172/JCI3491618521187
     [Google Scholar]
  31. ZhangL. GalloR.L. Antimicrobial peptides.Curr. Biol.2016261R14R1910.1016/j.cub.2015.11.01726766224
     [Google Scholar]
  32. MorizaneS. YamasakiK. MühleisenB. KotolP.F. MurakamiM. AoyamaY. IwatsukiK. HataT. GalloR.L. Cathelicidin antimicrobial peptide LL-37 in psoriasis enables keratinocyte reactivity against TLR9 ligands.J. Invest. Dermatol.2012132113514310.1038/jid.2011.25921850017
     [Google Scholar]
  33. MatsuzakiG. UmemuraM. Interleukin-17 family cytokines in protective immunity against infections: Role of hematopoietic cell-derived and non-hematopoietic cell-derived interleukin-17s.Microbiol. Immunol.201862111310.1111/1348‑0421.1256029205464
     [Google Scholar]
  34. LeeJ.S. TatoC.M. Joyce-ShaikhB. GulenM.F. CayatteC. ChenY. BlumenscheinW.M. JudoM. AyanogluG. McClanahanT.K. LiX. CuaD.J. Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability.Immunity201543472773810.1016/j.immuni.2015.09.00326431948
     [Google Scholar]
  35. LomholtG. Psoriasis: Prevalence, spontaneous course and genetics. A census study of skin diseases on the Faroe Islands.Doctoral dissertation, Ph. D Thesis. Copenhagen.
     [Google Scholar]
  36. FarberE.M. NallM.L. WatsonW. Natural history of psoriasis in 61 twin pairs.Arch. Dermatol.1974109220721110.1001/archderm.1974.016300200230054814926
     [Google Scholar]
  37. CaponF. BurdenA.D. TrembathR.C. BarkerJ.N. Psoriasis and other complex trait dermatoses: From Loci to functional pathways.J. Invest. Dermatol.2012132391592210.1038/jid.2011.39522158561
     [Google Scholar]
  38. VealC.D. CaponF. AllenM.H. HeathE.K. EvansJ.C. JonesA. PatelS. BurdenD. TillmanD. BarkerJ.N.W.N. TrembathR.C. Family-based analysis using a dense single-nucleotide polymorphism-based map defines genetic variation at PSORS1, the major psoriasis-susceptibility locus.Am. J. Hum. Genet.200271355456410.1086/34228912148091
     [Google Scholar]
  39. TiilikainenA. LassusA. KarvonenJ. VartiainenP. JulinM. Psoriasis and HLA-Cw6.Br. J. Dermatol.1980102217918410.1111/j.1365‑2133.1980.tb05690.x7387872
     [Google Scholar]
  40. HundhausenC. BertoniA. MakR.K. BottiE. Di MeglioP. ClopA. LaggnerU. ChimentiS. HaydayA.C. BarkerJ.N. TrembathR.C. CaponF. NestleF.O. Allele-specific cytokine responses at the HLA-C locus: Implications for psoriasis.J. Invest. Dermatol.2012132363564110.1038/jid.2011.37822113476
     [Google Scholar]
  41. CaponF. BijlmakersM.J. WolfN. QuarantaM. HuffmeierU. AllenM. TimmsK. AbkevichV. GutinA. SmithR. WarrenR.B. YoungH.S. WorthingtonJ. BurdenA.D. GriffithsC.E.M. HaydayA. NestleF.O. ReisA. LanchburyJ. BarkerJ.N. TrembathR.C. Identification of ZNF313 / RNF114 as a novel psoriasis susceptibility gene.Hum. Mol. Genet.200817131938194510.1093/hmg/ddn09118364390
     [Google Scholar]
  42. de CidR. Riveira-MunozE. ZeeuwenP.L.J.M. RobargeJ. LiaoW. DannhauserE.N. GiardinaE. StuartP.E. NairR. HelmsC. EscaramísG. BallanaE. Martín-EzquerraG. HeijerM. KamsteegM. JoostenI. EichlerE.E. LázaroC. PujolR.M. ArmengolL. AbecasisG. ElderJ.T. NovelliG. ArmourJ.A.L. KwokP.Y. BowcockA. SchalkwijkJ. EstivillX. Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis.Nat. Genet.200941221121510.1038/ng.31319169253
     [Google Scholar]
  43. TsoiL.C. SpainS.L. KnightJ. EllinghausE. StuartP.E. CaponF. DingJ. LiY. TejasviT. GudjonssonJ.E. KangH.M. AllenM.H. McManusR. NovelliG. SamuelssonL. SchalkwijkJ. StåhleM. BurdenA.D. SmithC.H. CorkM.J. EstivillX. BowcockA.M. KruegerG.G. WegerW. WorthingtonJ. Tazi-AhniniR. NestleF.O. HaydayA. HoffmannP. WinkelmannJ. WijmengaC. LangfordC. EdkinsS. AndrewsR. BlackburnH. StrangeA. BandG. PearsonR.D. VukcevicD. SpencerC.C.A. DeloukasP. MrowietzU. SchreiberS. WeidingerS. KoksS. KingoK. EskoT. MetspaluA. LimH.W. VoorheesJ.J. WeichenthalM. WichmannH.E. ChandranV. RosenC.F. RahmanP. GladmanD.D. GriffithsC.E.M. ReisA. KereJ. NairR.P. FrankeA. BarkerJ.N.W.N. AbecasisG.R. ElderJ.T. TrembathR.C. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity.Nat. Genet.201244121341134810.1038/ng.246723143594
     [Google Scholar]
  44. JordanC.T. CaoL. RobersonE.D.O. PiersonK.C. YangC.F. JoyceC.E. RyanC. DuanS. HelmsC.A. LiuY. ChenY. McBrideA.A. HwuW.L. WuJ.Y. ChenY.T. MenterA. Goldbach-ManskyR. LowesM.A. BowcockA.M. PSORS2 is due to mutations in CARD14.Am. J. Hum. Genet.201290578479510.1016/j.ajhg.2012.03.01222521418
     [Google Scholar]
  45. Di CesareA. Di MeglioP. NestleF.O. The IL-23/Th17 axis in the immunopathogenesis of psoriasis.J. Invest. Dermatol.200912961339135010.1038/jid.2009.5919322214
     [Google Scholar]
  46. HuntK.A. MistryV. BockettN.A. AhmadT. BanM. BarkerJ.N. BarrettJ.C. BlackburnH. BrandO. BurrenO. CaponF. CompstonA. GoughS.C.L. JostinsL. KongY. LeeJ.C. LekM. MacArthurD.G. MansfieldJ.C. MathewC.G. MeinC.A. MirzaM. NutlandS. Onengut-GumuscuS. PapouliE. ParkesM. RichS.S. SawcerS. SatsangiJ. SimmondsM.J. TrembathR.C. WalkerN.M. WozniakE. ToddJ.A. SimpsonM.A. PlagnolV. van HeelD.A. Negligible impact of rare autoimmune-locus coding-region variants on missing heritability.Nature2013498745323223510.1038/nature1217023698362
     [Google Scholar]
  47. KimG.K. Del RossoJ.Q. Drug-provoked psoriasis: Is it drug induced or drug aggravated?: Understanding pathophysiology and clinical relevance.J. Clin. Aesthet. Dermatol.201031323820725536
     [Google Scholar]
  48. YaoY. RichmanL. MorehouseC. de los ReyesM. HiggsB.W. BoutrinA. WhiteB. CoyleA. KruegerJ. KienerP.A. JallalB. Type I interferon: Potential therapeutic target for psoriasis?PLoS One200837e273710.1371/journal.pone.000273718648529
     [Google Scholar]
  49. van der FitsL. MouritsS. VoermanJ.S.A. KantM. BoonL. LamanJ.D. CornelissenF. MusA.M. FlorenciaE. PrensE.P. LubbertsE. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis.J. Immunol.200918295836584510.4049/jimmunol.080299919380832
     [Google Scholar]
  50. PrinzJ.C. Psoriasis vulgaris - a sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis.Clin. Exp. Dermatol.200126432633210.1046/j.1365‑2230.2001.00831.x11422184
     [Google Scholar]
  51. JinY. YangS. ZhangF. KongY. XiaoF. HouY. FanX. ZhangX. Combined effects of HLA-Cw6 and cigarette smoking in psoriasis vulgaris: A hospital-based case-control study in China.J. Eur. Acad. Dermatol. Venereol.200923213213710.1111/j.1468‑3083.2008.02951.x18702622
     [Google Scholar]
  52. ÖzdenM.G. TekinN.S. GürerM.A. AkdemirD. DoğramacıÇ. UtaşS. AkmanA. EvansS.E. BahadırS. ÖztürkcanS. İkizoğluG. ŞendurN. KöseO. BekY. YaylıS. CantürkT. TuranlA.Y. Environmental risk factors in pediatric psoriasis: A multicenter case-control study.Pediatr. Dermatol.201128330631210.1111/j.1525‑1470.2011.01408.x21615473
     [Google Scholar]
  53. TakeshitaJ. GrewalS. LanganS.M. MehtaN.N. OgdieA. Van VoorheesA.S. GelfandJ.M. Psoriasis and comorbid diseases.J. Am. Acad. Dermatol.201776337739010.1016/j.jaad.2016.07.06428212759
     [Google Scholar]
  54. DhanaA. YenH. YenH. ChoE. All-cause and cause-specific mortality in psoriasis: A systematic review and meta-analysis.J. Am. Acad. Dermatol.20198051332134310.1016/j.jaad.2018.12.03730590074
     [Google Scholar]
  55. OlivierC. The risk of depression, anxiety, and suicidality a. in patients with psoriasis: A population-based cohort study.Arch. Dermatol.2010146889189510.1001/archdermatol.2010.18620713823
     [Google Scholar]
  56. MrowietzU. KragballeK. ReichK. SpulsP. GriffithsC.E.M. NastA. FrankeJ. AntoniouC. ArenbergerP. BalievaF. BylaiteM. CorreiaO. DaudénE. GisondiP. IversenL. KeményL. LahfaM. NijstenT. RantanenT. ReichA. RosenbachT. SegaertS. SmithC. TalmeT. Volc-PlatzerB. YawalkarN. Definition of treatment goals for moderate to severe psoriasis: A European consensus.Arch. Dermatol. Res.2011303111010.1007/s00403‑010‑1080‑120857129
     [Google Scholar]
  57. McMillinB.D. MaddernB.R. GrahamW.R. A role for tonsillectomy in the treatment of psoriasis?Ear Nose Throat J.199978315515810.1177/01455613990780030810188351
     [Google Scholar]
  58. ThorleifsdottirR.H. SigurdardottirS.L. SigurgeirssonB. OlafssonJ.H. PetersenH. SigurdssonM.I. GudjonssonJ.E. JohnstonA. ValdimarssonH. HLA-Cw6 homozygosity in plaque psoriasis is associated with streptococcal throat infections and pronounced improvement after tonsillectomy: A prospective case series.J. Am. Acad. Dermatol.201675588989610.1016/j.jaad.2016.06.06127520394
     [Google Scholar]
  59. RevickiD. WillianM.K. SauratJ.H. PappK.A. OrtonneJ.P. SextonC. CamezA. Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: Results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis.Br. J. Dermatol.2008158354955710.1111/j.1365‑2133.2007.08236.x18047521
     [Google Scholar]
  60. SauratJ.H. StinglG. DubertretL. PappK. LangleyR.G. OrtonneJ.P. UnnebrinkK. KaulM. CamezA. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).Br. J. Dermatol.2008158355856610.1111/j.1365‑2133.2007.08315.x18047523
     [Google Scholar]
  61. LindqvistT. SalahL. GillstedtM. WennbergA. OsmancevicA. Methotrexate management in psoriasis: Are we following the guidelines?Acta Derm. Venereol.201898444945110.2340/00015555‑285729199349
     [Google Scholar]
  62. HarperR.A. Specificity in the synergism between retinoic acid and EGF on the growth of adult human skin fibroblasts.Exp. Cell Res.1988178225426310.1016/0014‑4827(88)90396‑53262523
     [Google Scholar]
  63. LeeJ.H. YounJ.I. KimT.Y. ChoiJ.H. ParkC.J. ChoeY.B. SongH.J. KimN.I. KimK.J. LeeJ.H. YooH.J. A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis.BMC Dermatol.20161611110.1186/s12895‑016‑0048‑z27455955
     [Google Scholar]
  64. OehrlS. OlaruF. KunzeA. MaasM. PezerS. SchmitzM. SchäkelK. Controlling the pro-inflammatory function of 6-sulfo LacNAc (slan) dendritic cells with dimethylfumarate.J. Dermatol. Sci.201787327828410.1016/j.jdermsci.2017.06.01628732748
     [Google Scholar]
  65. AnsteyA.V. Fumaric acid esters in the treatment of psoriasis - commentary on ‘Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: A prospective study’ by Wain et al. Br. J. Dermatol.2010162223723810.1111/j.1365‑2133.2009.09624.x20374246
     [Google Scholar]
  66. Fallah AraniS. NeumannH. HopW.C.J. ThioH.B. Fumarates vs. methotrexate in moderate to severe chronic plaque psoriasis: A multicentre prospective randomized controlled clinical trial.Br. J. Dermatol.2011164485586110.1111/j.1365‑2133.2010.10195.x21175564
     [Google Scholar]
  67. OehrlS. PrakashH. EblingA. TrenklerN. WölbingP. KunzeA. DöbelT. SchmitzM. EnkA. SchäkelK. The phosphodiesterase 4 inhibitor apremilast inhibits Th1 but promotes Th17 responses induced by 6-sulfo LacNAc (slan) dendritic cells.J. Dermatol. Sci.201787211011510.1016/j.jdermsci.2017.04.00528499587
     [Google Scholar]
  68. BissonnetteR. HaydeyR. RosophL.A. LyndeC.W. BukhaloM. FowlerJ.F. DelormeI. Gagné-HenleyA. GooderhamM. PoulinY. BarberK. JenkinP. LandellsI. PariserD.M. Apremilast for the treatment of moderate‐to‐severe palmoplantar psoriasis: Results from a double‐blind, placebo‐controlled, randomized study.J. Eur. Acad. Dermatol. Venereol.201832340341010.1111/jdv.1464729055155
     [Google Scholar]
  69. HaiderA.S. LowesM.A. GardnerH. BandaruR. DarabiK. ChamianF. KikuchiT. GilleaudeauP. WhalenM.S. CardinaleI. NovitskayaI. KruegerJ.G. Novel insight into the agonistic mechanism of alefacept in vivo: Differentially expressed genes may serve as biomarkers of response in psoriasis patients.J. Immunol.2007178117442744910.4049/jimmunol.178.11.744217513795
     [Google Scholar]
  70. JullienD. PrinzJ.C. LangleyR.G.B. CaroI. DummerW. JoshiA. DedrickR. NattaP. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): Mechanisms of action.Dermatology2004208429730610.1159/00007766015178911
     [Google Scholar]
  71. LebwohlM. TyringS.K. HamiltonT.K. TothD. GlazerS. TawfikN.H. WalickeP. DummerW. WangX. GarovoyM.R. PariserD. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.N. Engl. J. Med.2003349212004201310.1056/NEJMoa03000214627785
     [Google Scholar]
  72. LeonardiC.L. PowersJ.L. MathesonR.T. GoffeB.S. ZitnikR. WangA. GottliebA.B. Etanercept as monotherapy in patients with psoriasis.N. Engl. J. Med.2003349212014202210.1056/NEJMoa03040914627786
     [Google Scholar]
  73. PappK.A. PoulinY. BissonnetteR. BourcierM. TothD. RosophL. Poulin-CostelloM. SetterfieldM. SyrotuikJ. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population.J. Am. Acad. Dermatol.2012662e33e4510.1016/j.jaad.2010.07.02620850895
     [Google Scholar]
  74. ZabaL.C. Suárez-FariñasM. Fuentes-DuculanJ. NogralesK.E. Guttman-YasskyE. CardinaleI. LowesM.A. KruegerJ.G. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes.J. Allergy Clin. Immunol.2009124510221030.e395, 39510.1016/j.jaci.2009.08.04619895991
     [Google Scholar]
  75. PappK.A. LangleyR.G. LebwohlM. KruegerG.G. SzaparyP. YeildingN. GuzzoC. HsuM.C. WangY. LiS. DooleyL.T. ReichK. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).Lancet200837196251675168410.1016/S0140‑6736(08)60726‑618486740
     [Google Scholar]
  76. PappK.A. GriffithsC.E.M. GordonK. LebwohlM. SzaparyP.O. WasfiY. ChanD. HsuM.C. HoV. GhislainP.D. StroberB. ReichK. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: Final results from 5 years of follow-up.Br. J. Dermatol.2013168484485410.1111/bjd.1221423301632
     [Google Scholar]
  77. TausendW. DowningC. TyringS. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: Ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.J. Cutan. Med. Surg.201418315616910.2310/7750.2013.1312524800703
     [Google Scholar]
  78. RichP. SigurgeirssonB. ThaciD.P. OrtonneJ.P. PaulC. SchopfR.E. MoritaA. RoseauK. HarfstE. GuettnerA. MachacekM. PapavassilisC. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: A randomised, double-blind, placebo-controlled, phase II regimen-finding study.Br. J. Dermatol.20121682no10.1111/bjd.1207023362969
     [Google Scholar]
  79. SathishJ.G. SethuS. BielskyM.C. de HaanL. FrenchN.S. GovindappaK. GreenJ. GriffithsC.E.M. HolgateS. JonesD. KimberI. MoggsJ. NaisbittD.J. PirmohamedM. ReichmannG. SimsJ. SubramanyamM. ToddM.D. Van Der LaanJ.W. WeaverR.J. ParkB.K. Challenges and approaches for the development of safer immunomodulatory biologics.Nat. Rev. Drug Discov.201312430632410.1038/nrd397423535934
     [Google Scholar]
  80. LiuY. WuE.Q. BensimonA.G. FanC.P.S. BaoY. GanguliA. YangM. CifaldiM. MulaniP. Cost per responder associated with biologic therapies for Crohn’s disease, psoriasis, and rheumatoid arthritis.Adv. Ther.201229762063410.1007/s12325‑012‑0035‑722843208
     [Google Scholar]
  81. CowdenA Van VoorheesAS Introduction: History of psoriasis and psoriasis therapy.Treat. Psorias.200819
     [Google Scholar]
  82. GirdlestoneT. Observations on the effects of Dr. Fowler’s mineral solution in lepra and other diseases.Med. Phys. J.1806158629730130491249
     [Google Scholar]
  83. FarberE.M. History of the treatment of psoriasis.J. Am. Acad. Dermatol.199227464064510.1016/0190‑9622(92)70232‑51401327
     [Google Scholar]
  84. SquireB. On the treatment of psoriasis by an ointment of chrysophanic acid.Churchill1878
     [Google Scholar]
  85. HjorthN. NorgaardM. Tars. Psoriasis.New YorkMarcel Dekker1991473479
     [Google Scholar]
  86. GreavesM.W. WeinsteinG.D. Treatment of Psoriasis.N. Engl. J. Med.1995332958158910.1056/NEJM1995030233209077838193
     [Google Scholar]
  87. IngramJ.T. The approach to psoriasis.BMJ19532483659159410.1136/bmj.2.4836.59113082048
     [Google Scholar]
  88. LundbergI.E. GrundtmanC. LarssonE. KlareskogL. Corticosteroids-from an idea to clinical use.Best Pract. Res. Clin. Rheumatol.200418171910.1016/j.berh.2003.10.00315123034
     [Google Scholar]
  89. HenchP.S. KendallE.C. SlocumbC.H. PolleyH.F. Effects of cortisone acetate and pituitary ACTH on rheumatoid arthritis, rheumatic fever and certain other conditions.Arch. Intern. Med.195085454566610.1001/archinte.1950.0023010000200115411248
     [Google Scholar]
  90. SulzbergerM.B. WittenV.H. The effect of topically applied compound F in selected dermatoses.J. Invest. Dermatol.195219210110210.1038/jid.1952.7214955641
     [Google Scholar]
  91. GubnerR. Effect of aminopterin on epithelial tissues.Arch. Dermatol.195164668869910.1001/archderm.1951.0157012002300414867911
     [Google Scholar]
  92. RoenigkH.H.Jr AuerbachR. MaibachH.I. WeinsteinG.D. Methotrexate in psoriasis: Revised guidelines.J. Am. Acad. Dermatol.198819114515610.1016/S0190‑9622(88)80237‑83042816
     [Google Scholar]
  93. BenedettoAV The psoralens.An historical perspective.
     [Google Scholar]
  94. MelskiJ.W. TanenbaumL. ParrishJ.A. FitzpatrickT.B. BleichH.L. Oral methoxsalen photochemotherapy for the treatment of psoriasis: A cooperative clinical trial.J. Invest. Dermatol.197768632833510.1111/1523‑1747.ep12496022864273
     [Google Scholar]
  95. FischerT. AlsinsJ. Treatment of psoriasis with trioxsalen baths and dysprosium lamps.Acta Derm. Venereol.197656538339010.2340/000155555638339078625
     [Google Scholar]
  96. GreenC. FergusonJ. LakshmipathiT. JohnsonB.E. 311 nm UVB phototherapy—an effective treatment for psoriasis.Br. J. Dermatol.1988119669169610.1111/j.1365‑2133.1988.tb03489.x3203066
     [Google Scholar]
  97. PicotE. MeunierL. Picot-DebezeM.C. PeyronJ.L. MeynadierJ. Treatment of psoriasis with a 311-nm UVB lamp.Br. J. Dermatol.1992127550951210.1111/j.1365‑2133.1992.tb14850.x1467291
     [Google Scholar]
  98. StüttgenG. zur lokalbenhandlung von keratosen mit vitamin-A-saure.Dermatology19621242658010.1159/000255058
     [Google Scholar]
  99. WardA. BrogdenR.N. HeelR.C. SpeightT.M. AveryG.S. Isotretinoin.Drugs198428163710.2165/00003495‑198428010‑000026235105
     [Google Scholar]
  100. WeinsteinG.D. Safety, efficacy and duration of therapeutic effect of tazarotene used in the treatment of plaque psoriasis.Br. J. Dermatol.1996135s49323610.1111/j.1365‑2133.1996.tb15664.x9035703
     [Google Scholar]
  101. MorimotoS. KumaharaY. A patient with psoriasis cured by 1 alpha-hydroxyvitamin D3.Med. J. Osaka Univ.1985353-451544069059
     [Google Scholar]
  102. SmithE.L. WalworthN.C. HolickM.F. Effect of 1 α,25-dihydroxyvitamin D3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions.J. Invest. Dermatol.198686670971410.1111/1523‑1747.ep122763432423618
     [Google Scholar]
  103. KragballeK. WildfangI.L. Calcipotriol (MC 903), a novel vitamin D3 analogue stimulates terminal differentiation and inhibits proliferation of cultured human keratinocytes.Arch. Dermatol. Res.1990282316416710.1007/BF003726162164359
     [Google Scholar]
  104. BorelJ.F. FeurerC. GublerH.U. StähelinH. Biological effects of cyclosporin A: A new antilymphocytic agent.Agents Actions1994433-417918610.1007/BF019866867725970
     [Google Scholar]
  105. MuellerW. HerrmannB. Cyclosporin a for psoriasis.N. Engl. J. Med.19793011055510.1056/NEJM197909063011015460314
     [Google Scholar]
  106. GriffithsC.E.M. DubertretL. EllisC.N. FinlayA.Y. FinziA.F. HoV.C. JohnstonA. KatsambasA. LisonA-E. NaeyaertJ.M. NakagawaH. PaulC. VanaclochaF. Ciclosporin in psoriasis clinical practice: An international consensus statement.Br. J. Dermatol.2004150s67112310.1111/j.0366‑077X.2004.05949.x15115441
     [Google Scholar]
  107. National Psoriasis FoundationAvailable from:https://www.Psoriasis.Org/drug-
  108. NandikolS. Prescription auditing of corticosteriods in dermatology department at a tertiary care hospital: A retrospective study.
     [Google Scholar]
/content/journals/cis/10.2174/012210299X256032231127060853
Loading
A Review on Psoriasis Pathophysiology, Clinical Appearance, and Pharmacotherapeutic Interventions
Curr. Indian Sci. 2, E2210299X256032 (2024); https://doi.org/10.2174/012210299X256032231127060853
/content/journals/cis/10.2174/012210299X256032231127060853
/content/journals/cis/10.2174/012210299X256032231127060853
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Chronic skin disease; Inflammation; Phytotherapy; Psoriasis; Skin disorder; Treatments

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test